FDA Brief

Warning letters Drugs

FDA warning letter to

Medline Inc

High riskIssued May 28Posted Jun 2Center for Drug Evaluation and Research (CDER)

FDA warned Medline Inc about repeated Bacillus cereus contamination in its drug products and inadequate investigations.

What happened

FDA inspected Medline Industries, LP's drug manufacturing facility at 1710 South Lakeside Drive, Waukegan, Illinois, from October 6 to 14, 2025. FDA said the firm found Bacillus cereus (B. cereus), a bacterium, in finished drug product samples about nine times from June 2, 2023 to August 27, 2025 and in at least five manufacturing environment samples since January 2025. FDA cited these as current good manufacturing practice (CGMP) violations and said Medline did not adequately investigate the repeated contamination or correct root causes.

What FDA found

  1. FDA said Medline did not thoroughly investigate repeated Bacillus cereus contamination in finished drug samples and the manufacturing environment or fix the root cause.

    21 CFR 211.192
  2. FDA said Medline lacked adequate separate or defined areas, controls to prevent contamination or mix-ups, and operations in areas of adequate size.

    21 CFR 211.42(c)
  3. FDA said Medline did not establish and follow adequate written procedures for cleaning and maintenance of equipment.

    21 CFR 211.67(b)
  4. FDA said operators used cleaning tools without suitable gloves and then repeatedly touched drug product, and the firm identified objectionable aseptic (contamination-controlled) behaviors as a root cause of contamination.

    21 CFR 211.42(c)
  5. FDA said operators routinely deviated from procedures for cleaning and disinfecting equipment, including valves, and the firm identified inadequate cleaning as a root cause of Bacillus cereus contamination.

    21 CFR 211.67(b)
  6. FDA cited similar CGMP observations at other facilities in the company network, including inadequate investigations into out-of-specification results at Hartland, Wisconsin, showing inadequate management oversight.

What FDA wants

FDA tells Medline to correct the violations promptly and respond in writing within 15 working days with what it has done and how it will prevent recurrence; if it cannot finish, it must give reasons and a completion schedule. FDA also asks for independent assessments and remediation plans for contamination hazards, cleaning and disinfection, sterilization options, investigations, corrective actions, and aseptic practices.

Who should pay attention

  • drug manufacturers with cleanroom operations
  • companies that buy or distribute Medline drug products
  • quality teams handling microbial contamination and investigations

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk